hsa-mir-33a: Hsa-mir-33a is a microRNA that has been found to play a role in various types of cancer, including glioblastoma, hepatocellular carcinoma (HCC), prostate cancer, lung adenocarcinoma, and endometrial cancer [26][27][45][46][PMC9200351][PMC8843861][PMC8615810][PMC9789638][PMC8257864]. It has been shown to regulate the expression of neuropilin-2, inhibiting glioblastoma cell migration [26]. Depletion of hsa-mir-33a is associated with tumorigenesis and poor prognosis in HCC patients [27]. However, there is no evidence in the provided context to support the claim that hsa-mir-33a can interfere with the cisplatin resistance of HCC cells [28]. In liver cancer, miRNAs related to hsa-mir-33a are enriched in fatty acid synthesis and metabolism pathways [PMC8843861]. Hsa-mir-33a has also been found to be dysregulated in HIV patients and may be involved in lipid metabolism [PMC8615810]. In a study on endometrial cancer progression, hsa-mir-33a was identified as a hub gene in ceRNA networks [PMC9200351]. The gene body of SREBF2, including the hsa-mir-33a locus, was found to be hypomethylated and may contribute to the down-regulation of SREBF2 expression [PMC9789638]. Hsa-mir-33a is also involved in the regulation of MAP4K3 expression in gestational diabetes mellitus (GDM) [PMC8257864]. Overall, hsa-mir-33a has been implicated in various biological processes and diseases through its regulation of target genes.

MIR33A: MIR33A is a microRNA that has been studied in relation to ABCA1 protein levels in a MO cohort [PMC5085653]. The relative expression of MIR33A was found to be inversely correlated with ABCA1 protein levels [PMC5085653]. However, it is still unclear whether MIR33A affects plaque development by influencing endothelial cell function, as further evidence is needed [PMC8579465]. Additionally, the combinatory utilization of curcumin and a control sequence of MIR33A did not show any significant difference compared to the use of curcumin alone [PMC7401289].